No known allergy to aspirin
Patients must not have prior history of allergy or known hypersensitivity to nivolumab or ipilimumab
Known allergy to boron or excipients in the formulation
Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)
Patients with a known or documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
Known allergy to any of the study agents
Known allergy to enadenotucirev, nivolumab or their excipients
Known history of positive serum human anti-drug antibody (ADA), or known allergy to any component of ADCT-
Prior allergy or adverse reaction to methotrexate
No known allergy or adverse reaction (e.g., wound dehiscence) to poly-lactide-co-glycolide (PLG)
Patients with a latex allergy
Known in tolerance and allergy to cytarabine.
Known allergy to grapes or grape seed
Bovine product allergy
Known or suspected allergy or hypersensitivity to the study drug
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to shellfish
Milk allergy
Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients. .
Known history of contrast allergy that cannot be medically managed
EXCLUSION - TREATMENT: Known allergy to VZV vaccine
Known allergy to HCQ
Patients with known allergy or hypersensitivity to AG or venetoclax.
Doxycycline allergy
Known allergy to PEGylated products
Participants must not have a history of allergy to nivolumab, urelumab or cabiralizumab
Bupivacaine or liposomal bupivacaine sensitive or known allergy.
Known allergy to anthracyclines.
Allergy to any component of MSC suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen
History of allergy to merestinib or chemically related compounds
Patient has a history of allergy to red color food dye or any other component of Qapzola, placebo, or their diluents
Known allergy or hypersensitivity to IP
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Known allergy to grapes or grape seed
Patients with unconfirmed allergies to piperacillin-tazobactam, cefepime, aztreonam or vancomycin can be evaluated by an allergy/immunology specialist, after which they may become eligible by a consensus of the treating physician, trial investigator and the allergy/immunology specialist
Patients with a known allergy to Zometa or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
Patients with a known hypersensitivity/allergy to any of the standard of care agents used in this study or related compounds (e.g. platinum compounds) are excluded
Patients with an allergy, or have experienced any drug reaction to ketamine will be excluded
Known allergy to coenzyme Q
Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K
Known allergy to doxycycline or tetracycline
Known allergy to ODM- or any of the excipients.
Known or suspected allergy to lenvatinib or any agent given in the course of this trial
History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria?toxoid containing vaccine
Known allergy to PIO
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to lidocaine, fentanyl, midazolam, or propofol (may be used during tumor biopsy or injection)
Allergy or hypersensitivity to agents used within the treatment protocol
Patients who have known allergy to mebendazole
DONOR: Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test products
Patients with known allergy to bovine or murine products
Patients with known carboplatin or cisplatin allergy
Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.
Known allergy to sulfa or specific allergy to sulfonylurea drugs
Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol
Patients with a known allergy to cisplatin chemotherapy; patients with carboplatin allergy may be included if they tolerate a test dose of intravenous (IV) cisplatin given in monitored floor conditions
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Allergy to filgrastim, pegfilgrastim, or loratadine
Patients must not have a known history of yeast allergy; if patient has a questionable history of allergy to yeast, a yeast skin test can be performed; patients would be eligible if skin test is negative (note, patients may not be on tricyclic antidepressants at the time of yeast skin test)
Patient does not have known allergy to polyethylene glycol hydrogel (spacer material)
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Gold allergy
Known history of allergy to Captisol
Known or suspected allergy or hypersensitivity to sorafenib
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
Patients with a known history of allergy to soy products
MAIN STUDY COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi
Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Patients with NSAIDs allergies, known lactose allergy, a history of recent gastrointestinal (GI) bleed (less than  weeks), and those who are on therapeutic dose anticoagulants will be excluded from this protocol
History of allergy to penicillin or related antibiotic
Patients with an allergy or known hypersensitivity to fish
Known allergy to any of the agents or their ingredients used in this study
Allergy to oseltamivir or excipients
Known allergy to domperidone
Known or suspected allergy to sorafenib, everolimus, or any agent given in the course of this trial
Patients with latex allergy.
Patients who have an allergy to gold.
Corn allergy
History of allergy to KLH, QS-, OPT-, or glucan
Patient having known allergy to NSAID or Aspirin
Known allergy to doxorubicin or anthracyclines.
History of allergy or hypersensitivity to the device constituent or Inserter materials.
Subjects with hypersensitivity or allergy to tetracycline antibiotics or edetate disodium;
Patients with known allergy to bovine or murine products.
Patients with known allergy to MB
Known allergy(ies) to any component of CMB or LV.
Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty.
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Known allergy to hyaluronidase
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
DONOR: Known allergy to filgrastim (GCSF)
Allergy to measles vaccine or history of severe reaction to prior measles vaccination
Known history of allergy to Captisol
Soy allergy
History of allergy or untoward reaction to prior vaccination with vaccinia virus
Known history of positive serum human ADA, or known allergy to any component of ADCT-.
Known allergy(ies) to any component of CMB or CPA
Patients with known floxuridine, leucovorin (leucovorin calcium), or mitomycin (mitomycin C) allergy
Known allergy to boron, MLN, any of the study treatments, their analogues, or excipients.
Known allergy to both penicillin and sulfa antibiotics
No known allergy to platinum compounds
Known or suspected allergy to any agent given in the course of this trial
Allergy to ciprofloxacin (or other quinolones), acetylsalicylic acid, or indomethacin.
Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Have a known allergy to tomatoes or have never consumed tomatoes
Known allergy to thalidomide.
Allergy to ganciclovir or acyclovir
Has known or suspected allergy or sensitivity to any test materials, reagents, or WCE contrast materials
Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;
Patient has a history of allergy to red color food dye.
Known allergy to hyaluronidase
Subjects with a known allergy to polyethylene glycol hydrogel (spacer material) or contraindication to spacer products (Duraseal or SpaceOAR)
Known allergy or hypersensitivity to Investigational Product.
Patients with documented allergy to cephalosporins
Patient has a known allergy to both penicillin and sulfa
All patients who have received prior vaccination with vaccinia virus (for smallpox immunization) must not have a history of allergy to the vaccine
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Known history of allergy to Captisol
Patients with a known allergy to murine proteins or have had a documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, oregovomab, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
Known allergy to any of the drugs used in the study. (Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.)
Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine
Known or suspected allergy to gemcitabine or MLN, or any agent given in the course of this trial
Known or suspected allergy to irinotecan or MLN, or any agent given in the course of this trial
Known allergy to any of the study medications
A known allergy to any component of the HyperAcute-Lung immunotherapy or cell lines from which it is derived.
Patients who have known allergy to mebendazole or benzimidazole
Allergy or hypersensitivity to agents used within the treatment protocol
Known allergy to any of the compounds under investigation
Medically diagnosed lactose intolerance, lactose allergy or salicylate allergy
If patients meet any of the following they will be excluded:\r\n* Active infection requiring intravenous treatment or having an unexplained febrile illness (temperature maximum [Tmax] > . Fahrenheit [F]/. Celsius [C])\r\n* Known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association class  or ) or known lung (forced expiratory volume in  second [FEV] < %) disease, uncontrolled diabetes mellitus\r\n* Albumin allergy; patients with a known allergy will be excluded\r\n* Gadolinium allergy
Known or suspected allergy to pazopanib
Subjects with known allergy or hypersensitivity to doxorubicin, cyclophosphamide, or eribulin mesylate.
History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
Known or suspected allergy to ARQ 
Patients with a history of allergy to entinostat or other medications that have a benzamide structure (i.e. tiapride, remoxipride, and clebopride)
Known allergy to allopurinol for subjects assessed with PR following their second-line induction therapy.
Patients with a known allergy to any component of vorinostat, or a known allergy to temozolomide and/or isotretinoin.
Known or suspected allergy to sorafenib (BAY -) or any agent given in association with this trial
DONOR: Known allergy to G-CSF
Patients will be excluded if they have a known allergy to any of the drugs used in the study
Allergy to measles vaccine or history of severe reaction to prior measles vaccination.
Known allergy to bone cement,
Patients will be excluded if they have a known allergy to any of the drugs used in the study.
Any known allergy to the compounds under investigation
Patients with known allergy or hypersensitivity to IMGN
Known allergy to wheat, rice (contained in the placebo), orange or the sweetener, Stevis
Known allergy to hyaluronidase or any constituents of docetaxel formulation.
Bovine product allergy
Known allergy to any of the study drugs
Known allergy to BCG or MMC
Prior history of penicillin or streptomycin allergy
Patients with a soy allergy will be excluded
Known or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat)
The subject has a known allergy to tetracycline
Known allergy to macrolide antibiotics
Known allergy to any of the study agents
Allergy to either of the study medications or -fluorouracil
Nut allergy
Patient has a known allergy to bovine or porcine products.
Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane.
Has no known allergy to murine products or positive HAMA
Known allergy to any of the components used during vertebroplasty (polymethyl methacrylate [PMMA] bone cement)
Allergy to implant materials or dental glue.
Known allergy to treatment medication (vemurafenib)
Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.
Known allergy to study medications
History of significant drug-related allergy (such as anaphylaxis)
Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related compounds
Known allergy to doxycycline or other tetracycline antibiotics
History of allergy to Urelumab (BMS-) or related compounds
History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a prior biologic therapy
Known allergy to any of the study medications
Known or suspected allergy to sorafenib
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Known or suspected allergy to any agent given in the course of this trial
Allergy: known hypersensitivity to other recombinant human antibodies
Patients with known systemic allergy to bovine or murine products
Known allergy to any of the agents or their ingredients used in this study
Allergy to bupropion
Known allergy to adhesive tape
Known or suspected allergy to pamidronate or related products
Known allergy to EACA
Allergy to allopurinol
known allergy to both penicillin and sulfa drugs
Known allergy to soy or any soy-based food or supplement
Known allergy to local anesthetics
Known allergy to perampanel
History of an allergy to romiplostim
History of allergy to fentanyl
Allergy treatment with antigen injections
Known true tape allergy
No known allergy to ingredients of banana bread preparation (eggs, almonds and other nuts since the celery also has almond powder)
Known allergy to stevia
Allergy treatment with antigens injections
Patients with a known allergy or hypersensitivity to CHG are ineligible
Patients with an allergy to quinolones
Patients must have no known allergy or hypersensitivity to duloxetine or any of the inactive ingredients in the matching placebo
Known allergy to a probiotic preparation
Food allergy to any component of the supplement
History of allergy to investigational agent: ropivacaine or other amino amide analgesics
History of allergy to standard agent: propofol
Allergy to fentanyl
Allergy to gabapentin
No known allergy to diphenhydramine, lidocaine, antacid (aluminum hydroxide, magnesium hydroxide, and simethicone), doxepin, tricyclic antidepressants, or any known component of the drug formulation in the testing arms
Antibiotic allergy to study medication
Allergy to bone morphogenetic protein
Allergy to bovine collagen products
Patients with documented allergy to soy products.
Allergy to beef
History of allergy to fentanyl
History of allergy to fentanyl
Participant has a known allergy to melatonin or any ingredients of the study product or placebo
Patients must not have an allergy to latex
Patients with history of allergy or adverse reactions to sodium bicarbonate or normal saline
No known allergy to either ACE inhibitors or ?-blockers
Known allergy to phenylephrine
Doxycycline allergy
Allergy to gabapentin
Allergy to either Eucerin or MF
Known allergy or preexisting skin disease which prohibits use of menthol
Known allergy to a probiotic preparation
History of allergy to acetic acid
No allergy to finasteride or other five alpha reductase inhibitors
History of allergy to apixaban or Factor Xa inhibitors
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity
Known allergy to electrode adhesives or woven knit compression fabrics
RECIPIENT: Allergy treatment with antigens injections
Known allergy to LCM or LEV
Known history of allergy to any component or other contraindications to any Neurokinin- (NK) or -hydroxytryptamine  (-HT) receptor antagonists.
Individuals with a known allergy to lidocaine are not eligible
Women with an allergy to rapamycin or its derivatives
Documented allergy to apixaban and/or enoxaparin
Allergy to nicotine patch, nicotine lozenge, or varenicline
Patient has allergy to fish or is a vegetarian
Bovine product allergy.
Subjects with a known allergy to lidocaine
Patients with an allergy to Peridex/chlorhexidine solution
Has a history of significant allergy to calcitriol as determined by the investigator.
Has known allergy to Tcm sestamibi
Iodide or seafood allergy
Women with a known allergy to proflavine or acriflavine
Known allergy to adhesive tapes or other skin adhesives used in medical care
Allergy to sulfa or sulfa-containing medications
Allergy to sulfa or sulfa-containing medications
History of allergy to iodide drugs or shellfish (iodine allergy)
Prior history of hypersensitivity to pegylated liposomal doxorubicin or indocyanine green (ICG) allergy; caution should be taken if prior ICG allergy is noted
Patients with a known allergy to Benadryl
Subjects with established allergy to IV GBCA
Patients with history of allergy to hydrogel dressing or ongoing skin diseases
Has known allergy to Tc m sestamibi
Women with a known allergy to proflavine or acriflavine
Patients with allergy to regadenoson
Known allergy or anaphylactic reaction to indocyanine green (ICG).
Severe food or medication allergy
Known allergy to proflavine or acriflavine
History of multiple food and/or drug allergy
Has a known allergy to dextran or VBD (if intended to be used)
History of any anaphylactic reaction, any severe allergy, or any allergy to folate
Has a known allergy to dextran
Known allergy to FdCyd
Allergy to fluoroquinolones
Allergy to Brussels sprouts
Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergy
Nut or seed allergy
No known allergy to tree nuts
Participant must not have a history of allergy to erlotinib